IONS – ionis pharmaceuticals, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

IONS

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/17

10:01 am

ions

Rating for IONS

Low Report

Rating for IONS

Report

12/17

10:01 am

ions

Rating for IONS

Low Report

Rating for IONS

Report

12/17

07:06 am

ions

Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Low Report

Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

12/17

07:06 am

ions

Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Low Report

Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

12/15

03:44 pm

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/30

02:18 pm

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/30

02:18 pm

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/30

12:18 pm

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/30

12:18 pm

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/30

11:17 am

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/30

11:17 am

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/30

11:02 am

ions

Ionis Pharmaceuticals (NASDAQ:IONS) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $89.00 price target on the stock, up previously from $85.00.

Low Report

Ionis Pharmaceuticals (NASDAQ:IONS) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $89.00 price target on the stock, up previously from $85.00.

Report

10/30

10:59 am

ions

Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Low Report

Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Report

10/30

10:59 am

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/30

10:59 am

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/30

08:13 am

ions

Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.

Low Report

Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.

Report

10/30

06:13 am

ions

Rating for IONS

Medium Report

Rating for IONS

Report

10/30

06:13 am

ions

Rating for IONS

Medium Report

Rating for IONS

Report

10/16

01:56 pm

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/16

01:56 pm

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/8

12:23 pm

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/8

12:23 pm

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/8

11:48 am

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/8

11:48 am

ions

Rating for IONS

Low Report

Rating for IONS

Report

10/8

08:20 am

ions

Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..

Low Report

Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.